Pay in 4 interest-free payments of $5.06 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
The model, beginning in 2026 for Medicaid and 2027 for Medicare, is voluntary for drug manufacturers, state Medicaid programs, and Medicare Part D plans
The 2023 phase 2 double-blind, randomized controlled trial evaluating a GLP-1/GIP/glucagon receptor triagonist (retatrutide) in patients with the disease of obesity reported 24.2% weight loss at 48 weeks with 12 mg retatrutide
Sterile water is available for injection use such as intravenous, intramuscular and subcutaneous
See terms at checkout
US$ 24.87
US$ 20.85
US$ 28.02
US$ 21.75
US$ 26.70
US$ 28.40
US$ 24.58
US$ 28.88
US$ 25.81
US$ 23.44
US$ 29.09
